Search Results
Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma
Isatuximab + Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)
Quadruplets in Newly Diagnosed Transplant-Ineligible Myeloma
Best Treatment Options for Transplant Ineligible Myeloma Patients: Doublets-Triplets?
Clinic Conversation of the Week: How to Talk to Patients About the BENEFIT Trial in Multiple Myeloma
The #ASCO24 Hematology Round Up
Treating Transplant-Ineligible Multiple Myeloma
DARA+RVd in Pts w/Transplant Eligible Newly Diagnosed Multiple Myeloma after 24 Months Maintenance
Myeloma: Frontline Therapy for Transplant Ineligible Patients
GRIFFIN updates: D-RVd vs RVd in transplant-eligible patients with newly diagnosed multiple myeloma
OncoAlert Session Round Up at ASH 24 in Multiple Myeloma: pharmacologic Therapies: Refining Evidence
